Erythropoietin is a hypoxia-induced hormone that is essential for normal erythropoiesis. The production of recombinant human erythropoietin (rHuEpo) has revolutionized the treatment of anemia associated with chronic renal failure and chemotherapy, and has been used as prophylaxis to prevent anemia after surgery. The erythropoietin receptor is widely distributed in the cardiovascular system, including endothelial cells, smooth muscle cells and cardiomyocytes. Epo has potentially beneficial effects on the endothelium including anti-apoptotic, mitogenic and angiogenic activities. On the other hand, some reports suggest that rHuEpo may have pro-thrombotic or platelet-activating effects. Hypertension develops in 20-30% of renal patients treated with rHuEpo. Many patients with heart failure have anemia. Despite some potential adverse effects, early studies in heart failure patients with anemia suggest that rHuEpo therapy is safe and effective in reducing left ventricular hypertrophy, enhancing exercise performance and increasing ejection fraction. Further studies are warranted to define the role of rHuEpo in chronic heart failure and other cardiovascular settings.
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border of the kidney [13] and in the liver during fetal and lar stores and triggers 1 pS Ca channel activity, which is 21 neonatal development [14] . A variety of other tissues have sustained by the extracellular Ca entry through the been reported to express erythropoietin including bone channel itself [28] . Calcium channel proteins may also marrow macrophages [15] , trophoblasts [16] , breast glands become phosphorylated during the EpoR mediated activa- [17] , and astrocytes [18] .
tion [29] . In addition to erythroid precursors [30] , EpoR is also expressed on megakaryocytes [31] , VSMC [27, 32] , endo-3 . Novel erythropoiesis stimulating protein thelial cells [32] [33] [34] , skeletal myoblasts [35] , neuronal cells [36] , kidney cells [37] , breast carcinoma [38] and Novel erythropoiesis stimulating protein (NESP, ischemic retinal cells [39] . In the heart the EpoR is  Aranesp ) was designed and expressed using recombinant expressed in the epicardium and pericardium [40] . A DNA technology [9] . NESP has several amino acid soluble form of EpoR (containing exons 1-4) has been substitutions, creating two new consensus N-linked carbodescribed, resulting from alternate splicing [41, 42] . Soluhydrate attachment sites, which result in five oligosacble EpoR has been suggested to contribute to resistance to charide chains in NESP compared with three on rHuEpo.
erythropoietin therapy [43] , or to ineffective erythropoiesis NESP binds to the same receptor as does rHuEpo, although in myelodysplastic syndromes [44] . at slightly reduced affinity [9] . The major benefit of NESP is an increase in the serum half-life by approximately 3-fold over rHuEpo (25.3 vs. 8.5 h). NESP can be 4 . Erythropoietin and thrombosis administered weekly or every other week [9, 19] . The adverse events reported with NESP, including rates of One of the potential side effects of erythropoietin hypertension and vascular access thrombosis have been therapy is an increase in thrombotic events. In a prospecsimilar to those with rHuEpo. Although NESP has several tive trial, 618 dialysis patients were randomized to achieve amino acid substitutions, no neutralizing antibodies have a target hematocrit of 42% versus a target hematocrit of been detected, as has been reported for epoetin [20] .
greater than 30% in 615 control patients [45] . After 29 months, the relative risk of death in the high hematocrit 3 .1. Erythropoietin receptor (EpoR) group was 1.3 (95% confidence interval 0.9-1.9), and the trial was stopped. Factors such as exposure to intravenous EpoR is a transmembrane (type I) receptor with a iron and decreased dialysis adequacy may have been WSXWS motif in the extracellular domain. It belongs to contributory, but the increased doses of erythropoietin the cytokine receptor superfamily and consists of eight could also explain this result [45] . An increase in carexons (extracellular domains: 1-5; membrane spanning diovascular events, including vascular access thrombosis, domain: 6; intracellular domains: 7, 8) [21]. The intracellustroke and myocardial infarction, has been associated with lar domain does not possess any kinase activity. Epo a rapid rate of rise in hemoglobin [19] . In the Canadian induces homodimerization of EpoR, with subsequent actiMulticenter study, the overall rate of thrombosis was vation of the receptor associated Janus kinase 2 [22], 0.28 / patient year in rHuEpo treated patients versus 0.05 / leading to tyrosine phosphorylation of EpoR, signal transpatient year in controls [46] . In retrospective studies of ducer and activator of transcription factor 5 (Stat 5) [23] , patients receiving chronic hemodialysis, rHuEpo therapy as well as a variety of other targets (Fig. 1) . A number of resulted in a higher rate of PTFE graft thrombosis [47] . proteins with Src homology 2 (SH2) domains such as PI3
Darbepoetin alpha results in an increased rate of thromkinase become associated and are activated. PI3 kinase botic events, including pulmonary embolism when adsuppresses apoptosis via activation of its downstream ministered to patients receiving chemotherapy [48] . effector Akt [24] . The Epo-EpoR interaction also leads to
The concerns regarding thrombosis have been evaluated activation of ras / MAPK pathways [25] , and to activation in an animal model. RHuEpo administration resulted in a of nuclear factor-kB dependent transcription [26] . There nearly 3-fold increase in the content of platelets in the may be tissue or cell specific responses to Epo. For thrombi in an A-V shunt model, which reverted to normal example, it has been reported that MAP kinase, but not after cessation of erythropoietin administration [49] . A JAK2-STAT5, is activated by exposure of rat VSMC to variety of mechanisms have been cited for increased Epo [27] .
thrombosis with erythropoietin therapy [50] . ErythroOne of the major effects of the Epo-EpoR interaction is cytosis has been associated with thrombosis in young a rise in intracellular calcium levels. Epo binding to EpoR healthy athletes [51] , possibly because of increased blood leads to phosphorylation of PLC-g1 [28] . PLC-g1 is then viscosity [52] or an enhancement of platelet attachment to translocated from the cytosol to the plasma membrane, the subendothelium [53] . RHuEpo therapy has been rewhere it forms a complex with the EpoR. PLC-g1 activaported to shorten the bleeding time even before the tion leads to PIP hydrolysis with the generation of IP , correction of anemia [54] , indicating that the elevation of 2 3 21 which in turn induces the release of Ca from intracelluhematocrit cannot explain this effect. Some studies have release of Ca from intracellular stores, which in turn enhances extracellular Ca entry through channel channels.
found an increase in vWF, manifest as increased ristocetinto baseline at 8-12 months. A similar incremental reducinduced platelet aggregation [54] after rHuEpo therapy.
tion was noted in free protein S. Factor VIII antigen has also been increased in some studies However, other studies have found minimal or no [55] . Enhanced thrombin generation has also been reported adverse effects on hemostasis parameters [50] . In a group after rHuEpo therapy, manifest as an increase in the TAT of 17 patients with renal anemia including dialysis and complex in rHuEpo-treated dialysis patients, which peaked predialysis patients, a variety of coagulation parameters at 2 months of therapy [56] . The increment in TAT was
were assessed before and at 3 months and 1 year after comparable to that observed with myocardial infarction beginning erythropoietin therapy [58] . The only significant and was higher than that reported in DVT or DIC [56] .
change noted was a decrease in the total level of protein S Lower levels of protein C and S have been reported after at 3 months (from 131% to 120%), a change that did not rHuEpo therapy, which could contribute to elevated propersist at 1 year [58] . Marchi et al. [59] studied 30 thrombotic markers [54, 57] . Macdougall et al. [57] rehemodialysis patients with native AV fistulae, 16 receiving ported a reduction in total and free protein S, as well as rHuEpo and 14 receiving a placebo, with a prospective protein C after initiation of rHuEpo. Protein C levels at 3-year follow-up. There were no differences in the rates of baseline were 84.3% but decreased to 66.4% at 4 months, stenosis of AV fistulae in the two groups. Furthermore, the and returned to baseline at 8 months [57] . Total protein S rHuEpo-treated group did not have a significant difference decreased from 124.1% to 68.3% at 4 months and returned in F112, Factor VII, Factor XII, t-PA antigen, PAI-1 antigen, D-dimer, fibrinogen, protein C and S activities Epo binds to megakaryocytes, where it may contribute compared with the placebo-treated group [59] .
to megakaryocyte maturation [31] . In patients treated with rHuEpo, the platelet count may increase by 10-20% [66] or substantially more in thrombocytopenic patients with 5 . Effects on platelets chronic liver disease [67] . Recent data from a porcine model suggest that even modest rises in platelet count can Several studies have documented a decrease in the increase the propensity for arterial thrombosis [68] . bleeding time of dialysis patients after initiation of rHuEpo RHuEpo therapy has been reported to increase the mean therapy [54, 60] . Although this response could be due to platelet volume [69] with larger platelets being more active changes in the vessel wall or circulating proteins, several than smaller platelets [70] . lines of evidence suggest that at least part of the response is from direct action on platelets. Hemodialysis patients undergoing rHuEpo therapy have increased spontaneous 6 . Erythropoietin effects on the vascular endothelium platelet aggregation in whole blood (Table 1) , which reverses by withdrawing erythropoietin and can be inBinding studies with radio-iodinated recombinant human hibited by aspirin administration [61] .
erythropoietin demonstrated approximately 27 000 recepErythropoietin therapy in uremic rats leads to a normalitors per endothelial cell with a K in the nanomolar range d zation of the defect in thrombin stimulated rise in platelet [34] . Epo has a mitogenic and chemotactic effect on calcium influx [62] . RHuEpo therapy was associated with HUVEC and bovine adrenal capillary endothelial cells [34] 21 21
increased Ca uptake and increased Ca stores in the (Table 1) . Furthermore, Epo induces MMP-2 production, platelets [62] . Erythropoietin therapy of uremic patients proliferation and tube formation in EA.hy926 cells [71] . improves the intraplatelet signaling induced by thrombin These effects likely contribute to the ability of Epo to through tyrosine phosphorylation of proteins associated induce angiogenesis [71] [72] [73] [74] . Using small pieces of human with the cytoskeleton [63] . Enhanced transient platelet myocardial tissue, Jaquet et al. demonstrated that Epo was reactivity has been observed in dialysis patients treated equally effective to VEGF in promoting capillary outwith rHuEpo [64] and may contribute to a pro-thrombotic growth [74] . effect. Ando and colleagues [65] reported elevated platelet Epo stimulates the production of endothelin [75] , an microparticles (PMP) in uremic pre-dialysis patients and effect that is additive with Ang II or thrombin [72] . Epo ESRD patients compared to healthy controls [65] . The use also induces the production of PAI-1 in cultured HUVEC of Epo in dialysis patients was associated with a sig- [33] . Six proteins have been identified that are tyrosine nificantly higher PMP count compared to untreated paphosphorylated following stimulation of cultured HUVEC tients [65] . The infusion of rHuEpo at 100 U or 500 U / kg with rHuEpo. Of these proteins (94, 70, 42, 40, 29 and 25 in normal healthy male volunteers resulted in increased kDa), one has been identified as STAT5 [76] . A differenpercentages of P-selectin and CD63-positive platelets after tial display analysis of genes up-regulated in human stimulation by TRAP [66] . Furthermore, circulating levels vascular endothelium has been performed [77] . Eight of soluble P-selectin were also elevated, consistent with genes were identified that were up-regulated by rHuEpo. increased in vivo platelet activation [66] .
These included (i) proteins with vascular functionsthrombospondin-1 and myosin regulatory light chain; (ii) genes involved in gene transcription and / or translation Increased PAI-1 production
In healthy male volunteers given rHuEpo 100 or 500 U / kg Vascular smooth muscle sis or a history of thrombotic disorders. To evaluate the PI3 kinase pathway in rat aortic VSMC [94] and phosphoeffect of Epo on endothelial function in an animal model,
AkT mediates an anti-apoptotic effect [95] . There is a rabbits were given erythropoietin for 1 week [79] . Blood significant elevation in the expression of EpoR in the pressure and vascular resistance were significantly less hyperplastic intima from stenotic fistula in hemodialysis responsive to endothelium dependent vasodilators after patients receiving erythropoietin therapy [96] . Based on rHuEpo therapy [79] . Responses to endothelium-indepenthese effects it is possible that Epo administration contrident vasodilators did not change with rHuEpo therapy.
butes to the accelerated progression of atherosclerosis in These observations suggest that rHuEpo may selectively dialysis patients [97] . suppress endothelial NO synthase activity. This finding is in agreement with studies of cultured human endothelial cells in which incubation with rHuEpo decreased basal and 8 . Hypertension ACh-stimulated NO production, and depressed NO synthetase expression [80] . Although the direct effect of Hypertension develops or worsens in 20-30% of renal Epo on the vascular endothelium may suppress NO patients treated with rHuEpo [98] . Although the elevated synthetase, there appears to be a compensatory increase in blood pressure can usually be treated without serious NO production when Epo-induced erythrocytosis occurs.
consequences, hypertensive encephalopathy and seizures Transgenic mice that overexpress human erythropoietin occur rarely [99] . Increased blood pressure may occur in have higher plasma nitrate levels than control mice [81] , a dialysis patients as early as 2 weeks or up to 4 months factor that helps prevent thrombosis despite a high hematoafter the onset of therapy [98] , most commonly in patients crit (0.85). Similarly, rats with erythrocytosis induced by receiving dialysis, who have a history of hypertension [98] . exogenous erythropoietin administration have enhanced Animal models have mimicked the clinical scenario with a NO production, which helps maintain a normotensive state rise in blood pressure after rHuEpo most likely to occur in in these animals [82] .
uremic animals with a predisposition to hypertension [100] . Patients who are hypotensive may have a 10% increase in BP after starting erythropoietin [98] .
. Erythropoietin effects on vascular smooth muscle
Postulated mechanisms for erythropoietin-induced hycells pertension include increased viscosity, enhanced vascular reactivity due to the correction of hypoxia or vasoconstricRHuEpo has vasoconstrictor effects on isolated renal tive responses due to the correction of anemia. Some and mesenteric resistance vessels [83] and high concenevidence suggests that rHuEpo may lead to catecholamine trations have been shown to induce contractions of rat release and activation of the renin-angiotensin system. mesangial and aortic smooth muscle cells [84] . In cell Cirillo et al. reported a significant association between culture, rHuEpo raises the cytosolic calcium content of hematocrit and prevalence of hypertension [101] , while VSMC, with stimulation of PKC and PLC-g1 [75, 85] other studies have not demonstrated this correlation [102] . likely contributing to this process [86] . Epo has a synergisRHuEpo may have a direct vasopressor effect due to SMC 21 tic effect on rises in Ca concentration in response to contraction at the level of the small resistance vasculature norepinephrine [86, 87] , angiotensin II [85] and ET-1 [88] . [83] . The vasopressor effect may be due in part to the rise RhuEpo increases the mRNA and protein expression of in intracellular calcium levels, although in an animal angiotensin receptors types 1 and 2 ( Table 1 ). The increase model, Roger et al. reported an increase in BP in uremic in Ang II receptors sensitizes the cells to Ang II [89] . Epo SHR without an increase in cytosolic calcium levels [100]. inhibits IL-1b stimulated NO production in rat VSMC Epo stimulates increased ET-1 release in cultured endo- [86, 90] , potentially contributing to increased vasomotor thelial cells [72] , in isolated hind legs of rats [103] and in tone.
mice that overexpress erythropoietin [104] . ET-1 levels The increase of angiotensin II receptor on VSMC by have been reported to be elevated in some [105] but not all Epo not only affects vasomotor tone but also increases [106] studies in patients receiving rHuEpo. gene products that could enhance cell proliferation (TGFb, IGF-II, EGF, PDGF, c-fos) [89] . Induction of the expression of the proto-oncogenes c-myc, JunB, as well as 9 . Effects of erythropoietin on the heart transient induction of c-fos has been reported [91] , likely contributing to the dose-dependent mitogenic effects of RHuEpo produces a dose-dependent increase in neonatal 3 Epo on SMC, as indicated by H-thymidine incorporation rat cardiomyocyte proliferation, which was inhibited by [91, 92] . The mitogenic effects may be more pronounced tyrosine kinase, protein kinase C and phospholipase C when VSMC from SHR were used compared with WKY inhibitors [108] . Furthermore, ouabain, an inhibitor of
(Wistar-Kyoto) rats [93] , suggesting that hypertension Na ,K -ATPase activity, inhibited the stimulation of may 'prime' VSMC for a proliferative response to Epo. proliferation by rHuEpo [107] ( Table 1 ). The effects of Furthermore, Epo induces Akt phosphorylation through the rHuEpo on the myocyte cells appear to be related to the capacity of erythropoietin to stimulate Na ,K -ATPase with intravenous iron to patients with CHF improved activity, likely secondary to the activation of tyrosine NYHA functional class, EF, the number of hospitalized kinase and protein kinase C. In the myocardium from days, the dose of diuretics and slowed the rate of prouremic rats, there is a decrease in high affinity binding gression of renal failure [120] . Similar findings were seen 3 sites for [ H]ouabain which is restored by erythropoietin in 32 patients with anemia and CHF randomized to treatment. This finding suggests a mechanism for improved erythropoietin versus standard therapy [124] . Mancini et al. myocardial contractility in renal failure patients after performed a single blind randomized trial of Epo versus rHuEpo administration [108] .
placebo in patients with class III or IV CHF and HCT Patients with cyanotic congenital heart disease have ,35% [125] . After 3 months of therapy, there was a elevated Epo levels, which can induce erythrocytosis, with significant increase in peak VO of 1.7 ml / kg / min in the 2 subsequent hyperviscosity, exacerbation of heart failure, as rHuEpo treated group compared with a decline of 0.5 well as seizures and thromboembolic events. Mice overml / kg / min in the placebo cohort. The rHuEpo group also expressing the human Epo gene develop severe erythrohad an increased exercise duration and distance time of 6 cytosis (HCT50.80), resulting in decreased survival, min and an improved quality of life score [125] . Epo increased heart weights, and biventricular dilatation [109] .
therapy was well tolerated without thrombotic complicaIn contrast, mice lacking erythropoietin or erythropoietin tions or hypertension [125] . receptor die at embryonic days 13-15 and have reduced number of proliferating cardiac myocytes, resulting in ventricular hypoplasia [40] . This defect is probably due to 1 0. Future studies of erythropoietin therapy the severe anemia in these mice rather than a specific dependence on the Epo-EpoR signaling pathway in norThe Cardiovascular Risk Reduction by Early Anemia mal heart development [110] . Suzuki et al. rescued EpoRTreatment with Epoetin beta (CREATE) trial will investinull mice from embryonic lethality by expressing an EpoR gate the effect of early anemia correction on cardiovascular transgene under the control of a GATA-locus hematorisk reduction in patients with renal impairment not yet on poietic regulatory domain. These mice expressed EpoR renal replacement therapy [126] . The primary outcomes exclusively in the hematopoietic lineage, and displayed will be the change in left ventricular mass index (LVMI) normal blood vessel formation and cardiac development assessed by echocardiography at 1 year and the time to [110] .
first cardiovascular events. There will be two arms in the In dialysis patients, lower hemoglobin levels are associstudy: in the early intervention group, anemia correction ated with increased frequency of LVH, possibly through will begin with a Hb of 11-12.5 g / dl, with a target of renin-angiotensin system activation [111-113]. There is a 13-15 g / dl. In the late treatment arm, rHuEpo will be 30% increased risk of developing LV mass for each 0.5 administered for a Hb of ,10.5 g / dl with a target of g / dl drop in hemoglobin [111] . Chronic anemia increases 10.5-11.5 g / dl [126] . Erythropoietin may have additional the work load on the heart and increased LV mass is benefits on the heart that could further expand its carobserved in anemic patients with both ESRD and normal diovascular applications. RHuEpo has a demonstrated renal function. Partial correction of the anemia of renal benefit as a neuroprotective agent through its anti-apofailure by rHuEpo ameliorates LVH [114] . In ESRD ptotic, neurotrophic, antioxidant and angiogenic effects patients, the effect of rHuEpo on LVH may be dependent [127] . RHuEpo also protects against ischemic cell death by upon the degree of anemia prior to initiation of rHuEpo inhibiting the release of glutamate, a well-known neurotherapy [114] . In anemic patients with renal insufficiency, toxin, from neurons and attenuating glutamate toxicity rHuEpo therapy enhances cardiac output [115] , reduces [39, 128] . RhuEpo preserves mitochondrial function in the sympathetic tone, increases peripheral vascular resistance, skeletal muscle of patients with renal failure [129] and in improves coronary circulation and exercise tolerance anoxic endothelial cells in culture [130] . Therefore clinical [116] , induces regression of LVH [116] [117] [118] [119] and increases studies may be warranted to determine if rHuEpo affords LVEF in patients with LV dysfunction [117] [118] [119] [120] (Table  cardiac protection in clinical scenarios such as ischemic 2).
reperfusion injury. More than 79% of patients with class IV CHF have a Hb,12 g / dl, even if the degree of renal impairment is only mild [120] . Hemodilution accounts for nearly half of 1 1. Conclusions all cases of apparent anemia [121] . Several studies have demonstrated that the presence of anemia is associated
The use of erythropoietin has resulted in profound with increased mortality in patients with CHF [121] [122] [123] improvements in the health and quality of life of dialysis with an excess of approximately 13% for each 1 g / dl patients and has been a landmark achievement in the care decrease in the hemoglobin [122] . Importantly, the deof end-stage renal disease patients. Although classically creased survival was noted at relatively mild anemia described as a hormone that stimulates erythroid pre-(,11.6 g / dl in women and ,12.6 g / dl in men) [122] . 
